New Initiation of Long-Acting Opioids in Long-Stay Nursing Home Residents

Journal of the American Geriatrics Society

Volumn 64, Issue 9, 2016, Pages 1772-1778

  Pimentel, Camilla B ^a   Gurwitz, Jerry H ^b   Tjia, Jennifer ^a   Hume, Anne L ^c,d   Lapane, Kate L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

analgesics; long acting opioid; nursing home

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; LONG ACTING OPIOID; MORPHINE SULFATE; OPIATE DERIVATIVE; OXYCODONE; OXYMORPHONE; TRAMADOL; UNCLASSIFIED DRUG;

AGED; ARTICLE; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NURSING HOME PATIENT; PRESCRIPTION; UNITED STATES;

EID: 84987849619     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.14306     Document Type: Article

References (34)

1. Rigler SK, Shireman TI, Kallenbach L. Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries. Am J Geriatr Pharmacother 2007;5:91–99.
2. Pimentel CB, Briesacher BA, Gurwitz JH et al. Pain management in nursing home residents with cancer. J Am Geriatr Soc 2015;63:633–661.
3. Gurwitz JH, Field TS, Judge J et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005;118:251–258.
4. Miller M, Barber CW, Leatherman S et al. Prescription opioid duration of action and risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015;175:608–615.
5. U.S. Food and Drug Administration. Safety Warnings Regarding Use of Fentanyl Transdermal (Skin) Patches, 2005 [on-line]. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051739.htm Accessed May 19, 2016.
6. U.S. Food and Drug Administration. FDA Public Health Advisory: Important Information for the Safe Use of Fentanyl Transdermal System (Patch), 2007 [on-line]. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051257.htm Accessed May 19, 2016.
7. Dosa DM, Dore DD, Mor V et al. Frequency of long-acting opioid analgesic initiation in opioid-naïve nursing home residents. J Pain Symptom Manage 2009;38:515–521.
8. Dorsey ER, Rabbani A, Gallagher SA et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010;170:96–103.
9. Hartung DM, Middleton L, Markwardt S et al. Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication. Clin Ther 2015;37:114–123.
10. Valluri S, Zito JM, Safer DJ et al. Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care 2010;48:947–954.
11. Aspinall SE, Zhao X, Good CB et al. FDA warning and removal of rosiglitazone from VA national formulary. Am J Manag Care 2013;19:748–758.
12. Shah ND, Montori VM, Krumholz HM et al. Responding to an FDA warning—geographic variation in the use of rosiglitazone. N Engl J Med 2010;363:2081–2084.
13. Cohen A, Rabbani A, Shah N et al. Changes in glitazone use among office-based physicians in the U.S., 2003–2009. Diabetes Care 2010;33:823–825.
14. U.S. Centers for Medicare and Medicaid Services. MDS 3.0 RAI Manual, 2014 [on-line]. Available at http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/MDS30RAIManual.html Accessed May 19, 2016.
15. Saliba D, Buchanan J. Making the investment count: Revision of the Minimum Data Set for nursing homes, MDS 3.0. J Am Med Dir Assoc 2012;13:602–610.
16. Mor V, Intrator O, Unruh MA et al. Temporal and geographic variation in the validity and internal consistency of the Nursing Home Resident Assessment Minimum Data Set 2.0. BMC Health Serv Res 2011;11:78.
17. Fries BE, Schneider DP, Foley WJ et al. Refining a case-mix measure for nursing homes: Resource Utilization Groups (RUG-III). Med Care 1994;32:668–685.
18. Thomas KS, Dosa D, Wysocki A et al. The Minimum Data Set 3.0 Cognitive Function Scale. Med Care 2015 Mar 11 [Epub ahead of print].
19. Edelen MO, Saliba D. Correspondence of verbal descriptor and numeric rating scales for pain intensity: An item response theory calibration. J Gerontol A Biol Sci Med Sci 2010;65A:778–785.
20. Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology 1996;84:1243–1257.
21. Ripamonti CI, Santini D, Maranzano E et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23:vii139–vii154.
22. NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain [on-line]. Available at http://oralcancerfoundation.org/treatment/pdf/pain.pdf Accessed May 19, 2016.
23. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: Tailoring therapy to meet patient needs. Mayo Clin Proc 2009;84:602–612.
24. U.S. Centers for Medicare and Medicaid Services. Design for Nursing Home Compare Five-Star Quality Rating System: Technical Users' Guide, 2015 [on-line]. Available at http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandComplianc/Downloads/usersguide.pdf Accessed May 19, 2016.
25. U.S. Department of Justice. Practitioner's Manual: An Informational Outline of the Controlled Substances Act, 2006 [on-line]. Available at http://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf Accessed May 19, 2016.
26. Rogers WH. Regression standard errors in clustered samples. Stata Tech Bull 1993;3:19–23.
27. Lapane KL, Quilliam BJ, Chow W et al. Impact of revisions to the F-Tag 309 surveyors' interpretive guidelines on pain management among nursing home residents. Drugs Aging 2012;29:385–393.
28. Stevenson DG, Keohane LM, Mitchell SL et al. Medicare Part D Claims Rejections for Nursing Home Residents, 2006 to 2010. Am J Manag Care 2012;18:647–654.
29. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331–1346.
30. Koh NY, Koo WH. Polypharmacy in palliative care: Can it be reduced? Singapore Med J 2002;43:279–283.
31. Riechelmann RP, Krzyzanowska MK, O'Carroll A et al. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer 2007;15:1407–1412.
32. Currow DC, Stevenson JP, Abernethy AP et al. Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007;55:590–595.
33. Nauck F, Ostgathe C, Klaschik E et al. Drugs in palliative care: Results from a representative survey in Germany. Palliat Med 2004;18:100–107.
34. U.S. Food and Drug Administration. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), 2014 [on-line]. Available at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf Accessed May 19, 2016.